

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

February 7, 2021

**INHIBIKASE THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or Other Jurisdiction  
of Incorporation)

001-39676

(Commission File Number)

26-3407249

(IRS Employer  
Identification No.)

3350 Riverwood Parkway SE, Suite 1900  
Atlanta, Georgia

(Address of Principal Executive Offices)

30339

(Zip Code)

Registrant's Telephone Number, Including Area Code:

(678) 392-3419

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, \$0.001 par value	IKT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

On February 7, 2021, Inhibikase Therapeutics, Inc. (the "Company"), made available on the Company's website at [www.inhibikase.com](http://www.inhibikase.com) a corporate presentation which may be used in presentations to investors and analysts from time to time in the future. A copy of the Company's corporate presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Current Report on Form 8-K speaks only as of the date hereof. While the Company may elect to update the information in this Current Report on Form 8-K in the future, the Company disclaims any obligation to do so except to the extent required by applicable law.

The information furnished in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K is not incorporated by reference into any filings of the Company made under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in the filing unless specifically stated so therein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<u>Number</u>	<u>Description</u>
<u>99.1</u>	<u>Corporate Presentation of Inhibikase Therapeutics, Inc.</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 8, 2021

INHIBIKASE THERAPEUTICS, INC.

By: /S/ MILTON H. WERNER  
Milton H. Werner  
President and Chief Executive Officer

1. The first part of the document is a header section containing the title "THE EFFECTS OF THE 2008 FINANCIAL CRISIS ON THE UK ECONOMY" and the author's name "JAMES H. HARRIS".

[illegible]

**QUESTION** The following information was obtained from the records of the Department of Health and Human Services:






**60,000**



# Clarification of Abuse as Primary

- [illegible]

# Stressors Trigger Which Are Che to Neurodeger




Stressors trigger which are che to neurodeger. The diagram illustrates the relationship between stressors and neurodegeneration. The brain is shown with a lightning bolt striking it, indicating a trigger or stressor. Below the brain, a horizontal bar with vertical lines of varying heights represents a signal or data. The text 'Stressors Trigger Which Are Che to Neurodeger' is written above the diagram.

Stressors trigger which are che to neurodeger. The diagram illustrates the relationship between stressors and neurodegeneration. The brain is shown with a lightning bolt striking it, indicating a trigger or stressor. Below the brain, a horizontal bar with vertical lines of varying heights represents a signal or data. The text 'Stressors Trigger Which Are Che to Neurodeger' is written above the diagram.

## at-Synuclein Pl: Modification in

at-Synuclein Pl: Modification in




at-Synuclein Pl: Modification in

# Pathologic, e-A Parkinson's Pat

Pathologic, e-A Parkinson's Pat

Pathologic, e-A Parkinson's Pat



Pathologic, e-A Parkinson's Pat

Pathologic, e-A Parkinson's Pat

The Gateway that Convi

Pathologic, e-A Parkinson's Pat

Pathologic, e-A Parkinson's Pat


Pathologic, e-A Parkinson's Pat



# IKT-148009: A Novel, Selective, Reversible Inhibitor of Furf Administration Disease in Brain

IKT-148009 is a novel, selective, reversible inhibitor of furf administration disease in brain. It is a potent inhibitor of furf administration disease in brain, and it is a potent inhibitor of furf administration disease in brain.

IKT-148009




IKT-148009 is a novel, selective, reversible inhibitor of furf administration disease in brain. It is a potent inhibitor of furf administration disease in brain, and it is a potent inhibitor of furf administration disease in brain.

IKT-148009

IKT-148009

# IKT-148009: A Novel, Selective, Reversible Inhibitor of Furf Administration Disease in Brain

IKT-148009 restores



IKT-148009

# Gastrointestinaline Developmentopment

一、二、三、四、五、六、七、八、九、十、十一、十二、十三、十四、十五、十六、十七、十八、十九、二十、二十一、二十二、二十三、二十四、二十五、二十六、二十七、二十八、二十九、三十、三十一、三十二、三十三、三十四、三十五、三十六、三十七、三十八、三十九、四十、四十一、四十二、四十三、四十四、四十五、四十六、四十七、四十八、四十九、五十、五十一、五十二、五十三、五十四、五十五、五十六、五十七、五十八、五十九、六十、六十一、六十二、六十三、六十四、六十五、六十六、六十七、六十八、六十九、七十、七十一、七十二、七十三、七十四、七十五、七十六、七十七、七十八、七十九、八十、八十一、八十二、八十三、八十四、八十五、八十六、八十七、八十八、八十九、九十、九十一、九十二、九十三、九十四、九十五、九十六、九十七、九十八、九十九、一百

Il secondo punto riguarda la possibilità di ottenere informazioni sulla qualità dei servizi erogati. In questo caso, il sistema di monitoraggio deve essere in grado di raccogliere dati sulla soddisfazione dei clienti, sulla qualità delle prestazioni e sulla conformità ai requisiti di legge. Tali informazioni possono essere utilizzate per migliorare i servizi e per identificare le aree di miglioramento.


1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840.

1. *How many times did you use the Internet in the last 12 months?*  
 2. *How many times did you use the Internet in the last 6 months?*  
 3. *How many times did you use the Internet in the last 3 months?*  
 4. *How many times did you use the Internet in the last 1 month?*  
 5. *How many times did you use the Internet in the last 2 weeks?*  
 6. *How many times did you use the Internet in the last 1 week?*  
 7. *How many times did you use the Internet in the last 3 days?*  
 8. *How many times did you use the Internet in the last 24 hours?*  
 9. *How many times did you use the Internet in the last 12 hours?*  
 10. *How many times did you use the Internet in the last 6 hours?*  
 11. *How many times did you use the Internet in the last 3 hours?*  
 12. *How many times did you use the Internet in the last 1 hour?*  
 13. *How many times did you use the Internet in the last 30 minutes?*  
 14. *How many times did you use the Internet in the last 15 minutes?*  
 15. *How many times did you use the Internet in the last 5 minutes?*  
 16. *How many times did you use the Internet in the last 1 minute?*  
 17. *How many times did you use the Internet in the last 30 seconds?*  
 18. *How many times did you use the Internet in the last 15 seconds?*  
 19. *How many times did you use the Internet in the last 5 seconds?*  
 20. *How many times did you use the Internet in the last 1 second?*

[illegible][illegible]

© 2001 Blackwell Science Ltd *Journal of Internal Medicine* 250: 105–112

# Functional Rev Clearance of Tc Treatment



# Management 7 Development

Management 7 Development

Management 7 Development is a course that focuses on the development of management skills and knowledge. The course is designed for students who are interested in pursuing a career in management. The course covers a variety of topics, including the history of management, the functions of management, and the different types of organizations. Students will learn how to plan, organize, lead, and control an organization. They will also learn how to work effectively in a team and how to solve problems. The course is designed to be both challenging and rewarding, and it will provide students with the skills and knowledge they need to succeed in the workplace.

Management 7 Development is a course that focuses on the development of management skills and knowledge. The course is designed for students who are interested in pursuing a career in management. The course covers a variety of topics, including the history of management, the functions of management, and the different types of organizations. Students will learn how to plan, organize, lead, and control an organization. They will also learn how to work effectively in a team and how to solve problems. The course is designed to be both challenging and rewarding, and it will provide students with the skills and knowledge they need to succeed in the workplace.

Management 7 Development is a course that focuses on the development of management skills and knowledge. The course is designed for students who are interested in pursuing a career in management. The course covers a variety of topics, including the history of management, the functions of management, and the different types of organizations. Students will learn how to plan, organize, lead, and control an organization. They will also learn how to work effectively in a team and how to solve problems. The course is designed to be both challenging and rewarding, and it will provide students with the skills and knowledge they need to succeed in the workplace.

Management 7 Development is a course that focuses on the development of management skills and knowledge. The course is designed for students who are interested in pursuing a career in management. The course covers a variety of topics, including the history of management, the functions of management, and the different types of organizations. Students will learn how to plan, organize, lead, and control an organization. They will also learn how to work effectively in a team and how to solve problems. The course is designed to be both challenging and rewarding, and it will provide students with the skills and knowledge they need to succeed in the workplace.

Management 7 Development is a course that focuses on the development of management skills and knowledge. The course is designed for students who are interested in pursuing a career in management. The course covers a variety of topics, including the history of management, the functions of management, and the different types of organizations. Students will learn how to plan, organize, lead, and control an organization. They will also learn how to work effectively in a team and how to solve problems. The course is designed to be both challenging and rewarding, and it will provide students with the skills and knowledge they need to succeed in the workplace.

## Board of Directors

The Board of Directors is the highest governing body of a corporation. It is responsible for the overall management and control of the corporation. The Board of Directors is composed of a group of individuals who are elected by the shareholders of the corporation. The Board of Directors is responsible for making major decisions about the corporation, such as the appointment and removal of the CEO, the approval of the budget, and the declaration of dividends. The Board of Directors is also responsible for overseeing the management of the corporation and for ensuring that the corporation is operating in the best interests of its shareholders. The Board of Directors is a key component of the corporate governance structure, and it plays a vital role in the success of the corporation.

The Board of Directors is the highest governing body of a corporation. It is responsible for the overall management and control of the corporation. The Board of Directors is composed of a group of individuals who are elected by the shareholders of the corporation. The Board of Directors is responsible for making major decisions about the corporation, such as the appointment and removal of the CEO, the approval of the budget, and the declaration of dividends. The Board of Directors is also responsible for overseeing the management of the corporation and for ensuring that the corporation is operating in the best interests of its shareholders. The Board of Directors is a key component of the corporate governance structure, and it plays a vital role in the success of the corporation.



# Upcoming

## OBJECTIVES

### Pre-clinical Activities

- Chemical synthesis, purification, and characterization
- Cellular uptake, toxicity, and pharmacokinetics studies
- In vivo efficacy and safety studies

### Clinical Development Opportunities

- Phase I/IIa clinical trials for safety and efficacy
- Phase IIb/III clinical trials for efficacy and safety
- Phase IV clinical trials for long-term safety and efficacy

### Regulatory Pathway – FDA, EMA, and other regulatory agencies Research and Development

---